Viscosupplementation is a minimally invasive treatment for knee osteoarthritis. It involves the injection of hyaluronic acid into a knee joint to assist the viscous properties of synovial fluid. The procedure increases the joint’s functioning and reduces pain. Intra-articular viscosupplementation with hyaluronic acid is gaining acceptance as it is a non-invasive procedure compared to knee replacement. It is categorized into three product segments –– single-injection cycle, three-injection cycle, and five-injection cycle.
Technavio’s analysts forecast the global Viscosupplementation market to grow at a CAGR of 6.23% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global Viscosupplementation market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products in different regions.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Viscosupplementation Market 2016-2020
Technavio recognizes the following companies as the key players in the global Viscosupplementation market: Sanofi, Anika Therapeutics, Seikagaku, Fidia Farmaceutici, and Ferring Pharmaceuticals.
Other Prominent Vendors in the market are: Allergan, Contipro Biotech, DePuy Synthes, F. Hoffmann-La Roche, Galderma, HTL Biotechnology, Hyaltech, Expanscience Laboratoires, Lifecore Biomedical, Lipo Chemicals, Merz Aesthetics, Mylan, Nordic Drugs, Shandong Freda Biochem, Shanghai Jingfeng Pharmaceutical, Smith & Nephew, TEIJIN PHARMA, and TRB Chemedica International.
Commenting on the report, an analyst from Technavio’s team said: “The shift in consumer preference from cheaper five-injection cycle products to premium priced single-injection cycle products is a major positive trend being witnessed in the market in recent years. Despite its exorbitant cost, consumers are increasingly going for single-injection cycle viscosupplements because of shorter treatment time.”
According to the report, fast-growing geriatric population is the major driver driving growth in the market. A rising concern worldwide is the fast-growing elderly population, especially in the major countries such as Japan, South Korea, China, Germany, and the US. The geriatric people in these countries are affected by a wide range of chronic diseases such as cancer, liver, osteoarthritis, and kidney diseases.
Further, the report states that the increase in the number of substitutes for viscosupplementation is the major challenge being faced by the manufacturers in the market. NSAIDs, knee replacement devices, cyclooxygenase inhibitors, and joint arthroplasty devices are the substitutes for viscosupplements used in the treatment of knee osteoarthritis.
Sanofi, Anika Therapeutics, Seikagaku, Fidia Farmaceutici, Ferring Pharmaceuticals, Allergan, Contipro Biotech, DePuy Synthes, F. Hoffmann-La Roche, Galderma, HTL Biotechnology, Hyaltech, Expanscience Laboratoires, Lifecore Biomedical, Lipo Chemicals, Merz Aesthetics, Mylan, Nordic Drugs, Shandong Freda Biochem, Shanghai Jingfeng Pharmaceutical, Smith & Nephew, TEIJIN PHARMA, TRB Chemedica International.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook